Therapeutic T cell engineering

By Michel Sadelain, I. Rivière, S. Riddell. Nature, 2017

769 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Gene therapy comes of age (2018, positive): “Recent clinical studies have found that single infusions of T cells engineered with synthetic genes encoding a chimeric antigen receptor can produce durable responses in a subset of patients (5).”
Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses (2018, positive): “, 2008), regulating the activity of T cell subtypes independently may be an attractive strategy for optimizing the efficacy of CAR T cell therapy (Sadelain et al., 2017).”
Engineering strategies to overcome the current roadblocks in CAR T cell therapy (2019, background): “…cells in patients, one promising strategy is predicated on the use of T cell populations with higher percentages of less differentiated T cell subsets that have a greater proliferative capacity, such as naive T cells, stem cell memory T (T SCM ) cells and central memory T (T CM ) cells 50,118 (Fig.”